M1 Kliniken AG/€M12

1D1W1MYTD1Y5YMAX

About M1 Kliniken AG

M1 Kliniken AG, headquartered in Berlin, Germany, specializes in aesthetic medicine and plastic surgery services. Operating under the "M1 Med Beauty" brand, the company offers treatments such as breast augmentation, eyelid lifts, liposuction, and non-invasive procedures like hyaluronic acid and botulinum toxin injections. As of 2023, M1 Kliniken operates 58 specialist centers across ten countries, including Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, Hungary, Bulgaria, Romania, and Australia. The company also manages the M1 Schlossklinik in Berlin, a facility with six operating theaters and 35 beds. M1 Kliniken's strategic focus on specialization and centralized purchasing enables it to offer high-quality medical services at competitive prices.
Ticker
€M12
Sector
Health
Primary listing
XETRA
Employees
280
Headquarters
Berlin, Germany
Website
www.m1-kliniken.de

M1 Kliniken AG Metrics

BasicAdvanced
€374M
18.65
€1.08
1.09
€1.20
5.94%

Bulls say / Bears say

The core Beauty business is gaining quality as well as scale. H1 revenue rose 11.0% to €56.9m, while EBIT grew 23.8% to €18.6m and the margin reached 32.7%, well above the group’s 20% medium-term target. (M1 Kliniken AG)
The sale of HAEMATO Pharm has completed M1’s move towards a higher-margin aesthetic medicine pure play. Excluding the €4.1m non-cash deconsolidation charge, H1 adjusted EBIT rose 9.5% to €19.7m, while cash increased to €60.5m and the equity ratio reached 85.8%. (M1 Kliniken AG, Reuters)
M1 has a sizeable expansion runway if it can replicate its standardised clinic model internationally. Management is targeting Beauty revenue of €200m–€300m by 2029, compared with €56.9m in H1 2026, and the network has reached 59 centres across ten countries. (M1 Kliniken AG)
The reported group is now much smaller after the disposal. H1 revenue fell 58.3% to €76.6m, net profit declined to €9.72m from €11.62m and EPS fell to €0.52 from €0.63, so the headline earnings trend remains negative. (M1 Kliniken AG, Reuters)
The 2029 growth plan demands a substantial acceleration. Beauty revenue was €56.9m in H1 2026, yet management is aiming for €200m–€300m annually by 2029; achieving that will require rapid clinic openings without diluting the current high margins. (M1 Kliniken AG)
M1 competes partly through low prices, which leaves margins exposed if better-funded rivals enter or existing competitors become more aggressive. The company’s 2025 report specifically warns that price competition could reduce profitability or market share. (MarketScreener)
Data summarised monthly by Lightyear AI. Last updated on 16 Sept 2026.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.